These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 5999513)

  • 21. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy in advanced ovarian carcinoma.
    Hochster H
    J Clin Oncol; 1986 Jul; 4(7):1148. PubMed ID: 3723169
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
    Piver MS; Lele S; Barlow JJ
    Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The place of chemotherapy in the management of advanced ovarian carcinoma.
    Fennelly JJ
    J Ir Med Assoc; 1968 May; 61(371):165-71. PubMed ID: 5658600
    [No Abstract]   [Full Text] [Related]  

  • 25. [Intraperitoneal chemotherapy in ovarian carcinoma. Life prolonging in selected patients].
    Ottevanger PB
    Ned Tijdschr Geneeskd; 2009 Mar; 153(11):503-7. PubMed ID: 19402326
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
    J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 30. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma.
    Gadducci A; Viacava P; Cosio S; Fanelli G; Fanucchi A; Cecchetti D; Cristofani R; Genazzani AR
    Anticancer Res; 2003; 23(1B):549-56. PubMed ID: 12680144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
    Trimble EL; Thompson S; Christian MC; Minasian L
    Oncologist; 2008 Apr; 13(4):403-9. PubMed ID: 18448554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cytological changes induced by antiblastic celioclysis in ascitogenic ovarian carcinomas].
    Accinelli G; Cadenelli GP; Spreafichi F
    Quad Clin Ostet Ginecol; 1967 Feb; 22(2):76-84. PubMed ID: 5595818
    [No Abstract]   [Full Text] [Related]  

  • 33. [On hematopoietic changesin patients with malignant ovarian tumors during chemotherapy].
    Turbina IL; Mezentseva SK
    Vopr Onkol; 1965; 11(8):38-41. PubMed ID: 4957708
    [No Abstract]   [Full Text] [Related]  

  • 34. Bladder carcinoma associated with cyclophosphamide therapy for ovarian cancer occurring with a latency of 20 years.
    Volm T; Pfaff P; Gnann R; Kreienberg R
    Gynecol Oncol; 2001 Jul; 82(1):197-9. PubMed ID: 11426986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experience from palliative chemotherapy for advanced ovarian carcinoma - progress report on hospital with outpatient department at district level (author's transl)].
    Tilch G; Miesel U; Koall E
    Zentralbl Gynakol; 1982; 104(3):160-7. PubMed ID: 6177126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
    American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progress in the chemotherapy of ovarian cancer].
    Honetz N
    Wien Med Wochenschr; 1982 Jul; 132(13-14):319-24. PubMed ID: 6291259
    [No Abstract]   [Full Text] [Related]  

  • 38. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
    Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.